将KEYNOTE-048研究成果转化为头颈癌的实践建议。 - Suppr

Suppr

超能文献

Translating KEYNOTE-048 into practice recommendations for head and neck cancer.

作者信息

Szturz Petr, Vermorken Jan B

机构信息

Medical Oncology, Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland.

Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.

出版信息

Ann Transl Med. 2020 Aug;8(15):975. doi: 10.21037/atm.2020.03.164.

DOI:10.21037/atm.2020.03.164

PMID:32953775

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7475419/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c58f/7475419/36b37160b63d/atm-08-15-975-f1.jpg

相似文献

Translating KEYNOTE-048 into practice recommendations for head and neck cancer.

Ann Transl Med. 2020 Aug;8(15):975. doi: 10.21037/atm.2020.03.164.

Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040).

J Immunother Cancer. 2019 Apr 3;7(1):96. doi: 10.1186/s40425-019-0578-0.

[Immunotherapy for head and neck cancer : Highlights of the 2019 ASCO Annual Meeting].

HNO. 2019 Dec;67(12):905-911. doi: 10.1007/s00106-019-00761-8.

Consensus recommendations for management of head and neck cancer in Asian countries: a review of international guidelines.

Oral Oncol. 2013 Sep;49(9):872-877. doi: 10.1016/j.oraloncology.2013.05.010. Epub 2013 Jul 4.

Practice patterns and knowledge among California pediatricians regarding human papillomavirus and its relation to head and neck cancer.

Am J Otolaryngol. 2019 Jul-Aug;40(4):525-529. doi: 10.1016/j.amjoto.2019.04.011. Epub 2019 Apr 25.

Psychometric Validation of the M. D. Anderson Symptom Inventory-Head and Neck Module in the Spanish Language.

J Pain Symptom Manage. 2016 Jun;51(6):1055-61. doi: 10.1016/j.jpainsymman.2015.12.320. Epub 2016 Feb 17.

Best practice guidelines in the psychosocial management of HPV-related head and neck cancer: recommendations from the European Head and Neck Cancer Society's Make Sense Campaign.

Ann Oncol. 2016 Oct;27(10):1848-54. doi: 10.1093/annonc/mdw272. Epub 2016 Jul 25.

[Treatment of head and neck squamous cell carcinoma recurrences and distant metastases : Highlights of the 2019 ASCO Meeting].

HNO. 2019 Dec;67(12):898-904. doi: 10.1007/s00106-019-00773-4.

[The Immune Checkpoints Inhibitors for Head and Neck Cancer].

Gan To Kagaku Ryoho. 2019 Jan;46(1):21-27.

The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for head-and-neck carcinoma.

Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1190-8. doi: 10.1016/s0360-3016(01)01567-x.

引用本文的文献

DNA-PKcs Dysfunction Enhances the Antitumor Activity of Radioimmunotherapy by Activating the cGAS-STING Pathway in HNSCC.

J Inflamm Res. 2025 Mar 19;18:4177-4193. doi: 10.2147/JIR.S497295. eCollection 2025.

Predicting response to PD-1 inhibitors in head and neck squamous cell carcinomas using peripheral blood inflammatory markers.

Transl Oncol. 2025 Jan;51:102222. doi: 10.1016/j.tranon.2024.102222. Epub 2024 Dec 1.

Novel Effective Therapeutic Regimen for Recurrent/Metastatic Head and Neck Squamous Cell Cancer: Concurrent Triple Oral Metronomic Chemotherapy and Immunotherapy.

J Immunother Precis Oncol. 2024 Aug 19;7(3):171-177. doi: 10.36401/JIPO-24-1. eCollection 2024 Aug.

Effects of α‑solanine on human head and neck squamous cell carcinoma cells and human umbilical vein endothelial cells .

Oncol Lett. 2024 Jun 26;28(2):400. doi: 10.3892/ol.2024.14533. eCollection 2024 Aug.

Immunohistochemical study of Programmed Cell Death Ligand 1 (PDL1) expression by combined positive score using 22C3 clone in head and neck squamous cell carcinomas, its correlation with clinicopathological features and outcome.

J Oral Maxillofac Pathol. 2024 Jan-Mar;28(1):29-36. doi: 10.4103/jomfp.jomfp_339_23. Epub 2024 Apr 15.

Survival impact of sequential chemotherapy following pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma.

Int J Clin Oncol. 2024 Jun;29(6):764-770. doi: 10.1007/s10147-024-02508-0. Epub 2024 Mar 30.

Immune checkpoint inhibitor monotherapy is sufficient to promote microenvironmental normalization via the type I interferon pathway in PD-L1-expressing head and neck cancer.

Mol Oncol. 2024 Aug;18(8):1923-1939. doi: 10.1002/1878-0261.13633. Epub 2024 Mar 21.

Tolerability and efficacy of the cancer vaccine UV1 in patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma planned for first-line treatment with pembrolizumab - the randomized phase 2 FOCUS trial.

Front Oncol. 2024 Feb 7;14:1283266. doi: 10.3389/fonc.2024.1283266. eCollection 2024.

Clinical-genomic determinants of immune checkpoint blockade response in head and neck squamous cell carcinoma.

J Clin Invest. 2023 Oct 2;133(19):e169823. doi: 10.1172/JCI169823.

Construction and validation of a prognostic model based on stage-associated signature genes of head and neck squamous cell carcinoma: a bioinformatics study.

Ann Transl Med. 2022 Dec;10(24):1316. doi: 10.21037/atm-22-5427.

本文引用的文献

Management of recurrent and metastatic oral cavity cancer: Raising the bar a step higher.

Oral Oncol. 2020 Feb;101:104492. doi: 10.1016/j.oraloncology.2019.104492. Epub 2019 Dec 11.

Multicentre study on the consistency of PD-L1 immunohistochemistry as predictive test for immunotherapy in non-small cell lung cancer.

J Clin Pathol. 2020 Jul;73(7):423-430. doi: 10.1136/jclinpath-2019-205993. Epub 2019 Dec 10.

Immunotherapy for head and neck cancer: Recent advances and future directions.

Oral Oncol. 2019 Dec;99:104460. doi: 10.1016/j.oraloncology.2019.104460. Epub 2019 Nov 1.

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.

Lancet. 2019 Nov 23;394(10212):1915-1928. doi: 10.1016/S0140-6736(19)32591-7. Epub 2019 Nov 1.

Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.

Lung Cancer. 2019 Sep;135:188-195. doi: 10.1016/j.lungcan.2019.07.004. Epub 2019 Jul 8.

Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma.

Br J Cancer. 2019 May;120(10):1003-1006. doi: 10.1038/s41416-019-0449-y. Epub 2019 Apr 10.

Systemic treatment in elderly head and neck cancer patients: recommendations for clinical practice.

Curr Opin Otolaryngol Head Neck Surg. 2019 Apr;27(2):142-150. doi: 10.1097/MOO.0000000000000526.

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.

Lancet. 2019 Jan 12;393(10167):156-167. doi: 10.1016/S0140-6736(18)31999-8. Epub 2018 Nov 30.

Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade.

Clin Cancer Res. 2019 Feb 1;25(3):989-999. doi: 10.1158/1078-0432.CCR-18-1390. Epub 2018 Sep 11.

Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme.

Eur J Cancer. 2018 Sep;100:126-134. doi: 10.1016/j.ejca.2018.05.015. Epub 2018 Jul 13.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验